title: [Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation].
abstract: We report a 26-year-old man with primary refractory nodular sclerosis Hodgkin lymphoma against ABVD, ICE and autologous peripheral blood stem cell transplantation (auto-PBSCT), presenting with multiple epidural spinal cord compressions, paraplegia, and generalized lymphadenopathy. We administrated four cycles of brentuximab vedotin to achieve a complete response, and then conducted cord blood transplantation. This case raises the possibility of a new strategy for refractory Hodgkin lymphoma showing residual lesions after auto-PBSCT.
authors.affiliation: Department of Hematology, Japanese Red Cross Medical Center.
authors.forename: Sohsuke
authors.initials: S
authors.lastname: Meshitsuka
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
authors.forename: Yukifusa
authors.initials: Y
authors.lastname: Igeta
authors.forename: Sigeo
authors.initials: S
authors.lastname: Kawai
authors.forename: Toshio
authors.initials: T
authors.lastname: Kumasaka
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D005312:Fetal Blood / Q000637:transplantation*; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin